Skip to content
To the full analysis

GlaxoSmithKline Pharmaceuticals Stock: Growth

GLAXO.NS
$29.43Closing price of 20 Nov 2026MEQIRI Score 74 out of 100

GlaxoSmithKline Pharmaceuticals reported $412.37M in revenue for fiscal 2026, up 2.6% on the prior year, up 5.7% a year on average over up to five years. That makes three years of growth in a row.

Daily figure as of 22 Nov 2026

Revenue (Annual rate)
4.8%
per year from 2007 to 2026, per share 4.8%
Earnings (Annual rate)
3.4%
per year from 2007 to 2026, per share 5.6%
Free cash flow (Annual rate)
7.6%
per year from 2007 to 2026, per share 7.6%

Growth per Year by Period

What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.

since 2021since 2016since 2007
Revenue5.7%3.6%4.8%
Revenue per share5.7%3.6%4.8%
Earnings23.7%10.7%3.4%
Earnings per share23.7%10.7%5.6%
Free cash flow12.6%no data7.6%
Free cash flow per share12.6%no data7.6%

Growth Over Time

Since 2016 earnings grew faster than revenue, 10.7% against 3.6% a year, because the net margin rose from 14.0% to 27.1%. GlaxoSmithKline Pharmaceuticals has made a profit in every fiscal year since 2007. In the quarter to 30 Sep 2026 revenue grew 20.8% on the prior year quarter, after an average of 7.0% in the four quarters before.

Fiscal Years at a Glance

How Revenue and Earnings Grow

  • Revenue
  • Earnings
  • Free cash flow
Figures as a table
YearRevenueEarningsFree cash flow
2007$170.7M$59.45M$25.89M
2008$173.53M$59.08M$32.75M
2009$182.73M$63.78M$33.03M
2010$205.86M$54.8M$51.92M
2011$232.11M$60.49M$49.42M
2012$260.07M$46.25M$31.67M
2013$285.99M$60.63M$29.62M
2014$275.67M$51.97M$24.07M
2015$284.7M$41.13M$15.07M
2016$289.65M$40.59M−$10.05M
2017$313.83M$36.34M−$7.38M
2018$302.79M$37.84M$7.49M
2019$334.36M$48.06M$11.66M
2020$345.19M$10.06M$36.1M
2021$312.86M$38.65M$57.59M
2022$352.21M$182.87M$83.74M
2023$348.14M$65.9M$47.5M
2024$371.38M$63.66M$59.43M
2025$402.05M$100.09M$136.7M
2026$412.37M$111.79M$104.36M

Data and Required Disclosures

  • ; time horizon around 12 months
  • Rated Strong since 7 Nov 2026; valuation signal Overvalued since 22 Nov 2026
  • Price: closing price of 20 Nov 2026
  • Amounts in US dollars at the ECB reference rate of 20 Nov 2026 ($1 = ₹92.6752)
  • Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2026. MEQIRI calculates the score and fair value itself every night.
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy